{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Reference to Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA), Table 1",
        "description": "Reference from the Protocol Amendment Summary table to a change in a footnote in the SoA."
      },
      {
        "id": "ref_2",
        "name": "Reference to Study Assessments",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference from the Protocol Amendment Summary table to details about screening site procedures."
      },
      {
        "id": "ref_3",
        "name": "Reference to COVID-19 Vaccine Risk Assessment",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference from Section 2.3.1.1 regarding potential risks and mitigation measures for the COVID-19 vaccine."
      },
      {
        "id": "ref_4",
        "name": "Reference to Dose Modification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference from Table 3 (Potential Risks and Mitigation Strategy) to dose modification or discontinuation procedures."
      },
      {
        "id": "ref_5",
        "name": "Reference to Adaptive Protocol Features Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference from Section 4.1 to the table describing adaptive design features."
      },
      {
        "id": "ref_6",
        "name": "Reference to Dose Modification Criteria Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "description": "Reference from Table 4 (Adaptive Protocol Features) to the criteria for dose modification."
      },
      {
        "id": "ref_7",
        "name": "Reference to Exclusion Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference from Table 5 (Lifestyle Considerations) regarding blood donation restrictions."
      },
      {
        "id": "ref_8",
        "name": "Reference to Contraceptive Guidance",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference from Table 5 (Lifestyle Considerations) to appropriate contraceptive methods."
      },
      {
        "id": "ref_9",
        "name": "Reference to Inclusion Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference from Table 5 (Lifestyle Considerations) regarding start times for contraceptives."
      },
      {
        "id": "ref_10",
        "name": "Reference to Discontinuation Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "Reference to the Schedule of Activities (SoA, Section 1.3) for data collection upon study intervention discontinuation."
      },
      {
        "id": "ref_11",
        "name": "Reference to Pregnancy Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference from Section 7.1 regarding discontinuation from study intervention due to pregnancy."
      },
      {
        "id": "ref_12",
        "name": "Reference to Discontinuation Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL",
        "description": "Reference from Section 8.2.3 (Electrocardiograms) to QTc withdrawal criteria."
      },
      {
        "id": "ref_13",
        "name": "Reference to Clinical Laboratory Tests",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 8.2.4 to the list of clinical laboratory tests to be performed."
      },
      {
        "id": "ref_14",
        "name": "Reference to AE/SAE Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Reference from Section 8.3 to procedures for recording, evaluating, and reporting AEs and SAEs."
      },
      {
        "id": "ref_15",
        "name": "Reference to Lost to Follow-up Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference from Section 8.3.3 to the definition of lost to follow-up."
      },
      {
        "id": "ref_16",
        "name": "Reference to Genetics Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference from Section 8.3.6 stating that biobanked samples will not be used for genetic testing."
      },
      {
        "id": "ref_17",
        "name": "Reference to Copper/Molybdenum Measurement",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference from Section 8.5 to details of molybdenum measured in food, drinks, urine, and feces."
      },
      {
        "id": "ref_18",
        "name": "Reference to Pharmacodynamics Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Reference from Section 8.8 (Biomarkers) to details of copper and ceruloplasmin measurements."
      },
      {
        "id": "ref_19",
        "name": "Reference to Populations for Analysis Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8",
        "sectionTitle": "Populations for Analysis",
        "description": "Reference from Section 9.3 to the table defining analysis populations."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Results obtained from studies of ALXN1840 and ammonium tetrathiomolybdate in participants with WD; see the IB.",
        "annotationType": "Reference",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_2",
        "text": "Limited nonclinical data on copper elimination with tetrathiomolybdate suggested copper excretion may be at least maintained or increased with repeated dosing (refer to the current IB).",
        "annotationType": "Reference",
        "instanceType": "CommentAnnotation",
        "sourceSection": "4.2",
        "pageNumber": 27
      },
      {
        "id": "annot_3",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Current protocol amendment to clarify study procedures in the US to facilitate participant recruitment.",
        "amendmentNumber": "Amendment 3.1 (US)"
      },
      {
        "id": "ver_2",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Previous protocol amendment.",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Previous protocol amendment.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Previous protocol amendment.",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_5",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original approved protocol.",
        "amendmentNumber": "Original Protocol"
      }
    ],
    "summary": {
      "referenceCount": 19,
      "annotationCount": 3,
      "versionCount": 5
    }
  }
}